Cereno Scientific reports insider share purchase
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that an insider share purchase has been completed. Sten R. Sörensen, CEO of Cereno, purchased a total of 65,000 shares on August 31, 2023, to a value of 1.50 per share on the Nasdaq First North Growth Market marketplace.Sten R. Sörensen, CEO, owns a total of 1,163,514 shares and 250,000 warrants of Series 2019/2023 NO1, 666,666 warrants of Series KPO, and 25,000 warrants of Series 3 (TO3) in the company after the purchase. For further